Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Patient Education
Share your love
Nicox Reveals Successful Phase 3 Glaucoma Eye Drop
Nicox SA announced the results of its pivotal Mont Blanc Phase 3 trial, which compared the efficacy of its novel nitric oxide-donating bimatoprost eye drop, NCX 470, against latanoprost in reducing intraocular pressure (IOP) in patients suffering from open-angle glaucoma…
Innovent’s nAMD Drug Succeeds in Phase 2 Trial
Innovent Biologics announced that its second Phase 2 clinical trial of efdamrofusp alfa (R&D code: IBI302), a high-dose recombinant human VEGFR-Fc-Human CR1 fusion protein injection, has achieved its primary endpoint in treating Chinese subjects with neovascular age-related macular degeneration (nAMD).…
Beyond Appearance: The Health Implications of Eye Color
Eye color, a key trait that contributes to the uniqueness of an individual’s appearance, is determined by multiple genetic factors and can signify more than just aesthetic differences. It involves the complex interplay of genetics, melanin distribution in the iris,…
Congress Moves to Adjust Medicare Payments for Physicians
On March 8, Congress approved a partial government funding bill that introduces policies to mitigate reductions to the Medicare Physician Fee Schedule (MPFS), initially implemented on January 1. This new legislation decreases the cut from -3.37% to -1.69%, effective from…
2023 Recap: Top 20 Ophthalmic Collaborations of the Year
As we bid farewell to 2023, it’s time to reflect on the remarkable collaborations that have shaped the landscape of ophthalmic innovation. The past year witnessed groundbreaking partnerships between pharmaceutical giants, tech innovators, and research institutions, all aimed at advancing…
Top 12 Gene Therapies for Eye Diseases and Blindness
In a groundbreaking era of medical research, scientists and clinicians are spearheading novel gene therapies that hold promise for transforming the landscape of eye disease treatment. These cutting-edge interventions address a spectrum of conditions ranging from Usher Syndrome and retinoschisis…
2023 Recap: Top 15 Ophthalmic Medical Devices
In a groundbreaking year for ophthalmic advancements, 2023 has witnessed the launch of cutting-edge medical devices that promise to reshape the landscape of eye care. From augmented reality headsets to innovative surgical systems, the field is experiencing a wave of…
A Comprehensive Guide for Workplace Eye Wellness Month
In the modern workplace, maintaining eye health has become increasingly crucial, especially as many professions demand prolonged periods of screen time. Recognizing the significance of this issue, Workplace Eye Wellness Month is observed to raise awareness about the importance of…
GRF Allocates $2.5M Grant for Glaucoma Research
The Glaucoma Research Foundation (GRF) announced an unprecedented $2.5 million allocation in annual research grants, marking the most significant investment in its 46-year history dedicated to pioneering efforts towards treating glaucoma and vision loss. Understanding Glaucoma and Its Impact Glaucoma…
OcuTerra’s Nesvategrast Misses Mark in Diabetic Retinopathy Trial
OcuTerra Therapeutics announced the topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial, evaluating the efficacy of nesvategrast (OTT166). Nesvategrast, an innovative RGD integrin inhibitor formulated as an eye drop, was under investigation for its…